GHK-CU 50 mg
GHK-Cu 50 mg Dragon Pharma — Overview
GHK-Cu Dragon Pharma 50 mg delivers fifty milligrams of glycyl-L-histidyl-L-lysine copper(II) per vial — the same copper-binding tripeptide as the standard 10 mg vial, in a larger-volume format designed for extended runs, higher daily doses, or users who want to avoid frequent reconstitution. A single 50 mg vial covers approximately 16 days at 3 mg/day, or a full 7-week maintenance run at 1 mg/day — making it the practical choice for anyone running GHK-Cu as an ongoing protocol rather than a one-off addition.
GHK-Cu is a naturally occurring human tripeptide that declines from approximately 200 ng/mL in young plasma to around 80 ng/mL by age 60. The injectable form restores physiological concentrations and activates collagen synthesis, hair follicle stimulation, extracellular matrix remodeling, and anti-inflammatory signaling simultaneously. This page covers compound biology, dosing and reconstitution specifics for the 50 mg vial, comparison with other repair peptides, and how to integrate GHK-Cu into longer cycle protocols. Available at Steroid Warehouse alongside the full Dragon Pharma peptide range including BPC-157 and TB-500.
About the Compound: GHK-Cu
GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a tripeptide–copper complex first isolated from human plasma albumin by Loren Pickart in 1973. In healthy young adults, plasma GHK-Cu concentrations are approximately 200 ng/mL; by age 60 this has declined to around 80 ng/mL — tracking closely with the loss of regenerative tissue capacity observed in older skin, hair, and connective tissue. The tripeptide functions as a biological copper chaperone: it chelates Cu²⁺ with high affinity and delivers it to copper-dependent enzymes including lysyl oxidase (collagen and elastin cross-linking), superoxide dismutase-1 (antioxidant defense), and cytochrome c oxidase (mitochondrial function).
GHK-Cu operates through multiple parallel pathways — MMP/TIMP coordination for extracellular matrix turnover, TGF-β and FGF signaling for fibroblast activation, VEGF stimulation for angiogenesis, and NF-κB suppression for anti-inflammatory effect. This breadth of action across different signaling networks is why GHK-Cu produces measurable changes in skin, hair follicle biology, joint and scar tissue quality, and systemic oxidative load — rather than acting through a single receptor.
The 50 mg vial is supplied as lyophilized powder. It is functionally identical in potency and purity to the 10 mg vial — the difference is volume and economics. At 3 mg/day (hair loss protocol), the 50 mg vial covers approximately 16 days; at 1 mg/day (maintenance), it covers a full 7-week cycle. Users running back-to-back cycles or stacking GHK-Cu into a multi-peptide protocol will find the 50 mg format significantly more practical.
What GHK-Cu Does
GHK-Cu activates a wider range of repair and remodeling pathways simultaneously than most injectable peptides, driven by its role as a copper-delivery molecule and a direct signaling agent in tissue biology:
- Collagen and elastin synthesis — stimulates fibroblast upregulation of collagen types I and III and elastin production; activates lysyl oxidase (copper-dependent enzyme) for proper structural cross-linking; the cumulative result over a 6–8 week run is measurable improvement in skin firmness, connective tissue resilience in tendons and ligaments, and joint matrix integrity.
- Extracellular matrix remodeling — coordinates MMP and TIMP expression to clear damaged collagen and replace it with new matrix; prevents fibrosis and excess degradation simultaneously; directly relevant for scar remodeling, chronic tendon issues, and post-injury tissue normalization.
- Hair follicle stimulation — extends anagen (active growth) phase; increases dermal papilla cell proliferation and follicle size; reduces early catagen entry; the mechanism is independent of DHT signaling, making GHK-Cu effective for androgenic hair loss on trenbolone, boldenone, and DHT-derived compound cycles where 5α-reductase inhibitors are ineffective.
- Anti-inflammatory and antioxidant activity — suppresses IL-1β, IL-6, TNF-α, and NF-κB; activates SOD1 and catalase; reduces oxidative collagen damage; of particular relevance on AAS cycles where systemic oxidative load is chronically elevated.
- Angiogenesis and wound healing — stimulates VEGF and FGF2 for new capillary formation; accelerates keratinocyte and fibroblast migration into wound and repair sites; documented efficacy in chronic wound and skin damage models.
- Nerve repair — promotes NGF production and Schwann cell activity; supports peripheral nerve regeneration after injury.
Who It Is For
The 50 mg vial suits the same compound applications as the 10 mg format but is specifically the right choice for certain use profiles:
- What differentiates GHK-Cu from injury-focused repair peptides: unlike BPC-157, which primarily targets acute structural injury (tendon, ligament, gut) through GH receptor and FAK pathway activation, GHK-Cu is a systemic tissue remodeling agent with deeper documented effects on skin quality, collagen architecture, and hair follicle biology. BPC-157 produces faster results on acute injury; GHK-Cu delivers broader regenerative change across skin, scalp, and connective tissue over a sustained run. The mechanisms are complementary and the compounds can be run together.
- When the 50 mg vial is the better choice: users running 3 mg/day for hair loss prevention (the 50 mg vial covers ~16 days at this dose — four vials cover a full 8-week cycle); users on back-to-back GHK-Cu cycles; users stacking GHK-Cu into a multi-peptide protocol alongside BPC-157, TB-500, or Ipamorelin where reconstituting multiple vials at low frequency is more practical; users preferring fewer reconstitution events over a longer run.
- When to choose something else: for a short single cycle at low dose (1 mg/day × 4 weeks = 28 mg total), the 10 mg vial is sufficient; for acute targeted injury repair, BPC-157 or the BPC-157 + TB-500 blend delivers faster focused results; for systemic immune function support, Thymosin Alpha-1 is the appropriate compound.
GHK-Cu vs Alternatives
| Compound | Key Differences | Choose GHK-Cu When | Choose Alternative When |
|---|---|---|---|
| BPC-157 — Dragon Pharma | Body Protection Compound; targets tendon, ligament, muscle, and gut healing via GH receptor and FAK/paxillin signaling; faster acute repair; no direct copper-enzyme activity, hair follicle mechanism, or ECM cross-linking | Primary goals are skin quality, collagen architecture, or hair follicle support on an extended run; GHK-Cu and BPC-157 can be run together for additive recovery effects via non-overlapping mechanisms | Acute localized injury — torn tendon, muscle tear, gut damage from orals — where BPC-157's targeted structural repair delivers faster and more specific results |
| TB-500 (Thymosin Beta-4) — Dragon Pharma | Actin-sequestering peptide; promotes cell migration and systemic anti-inflammatory healing across muscle, tendon, and connective tissue via β-thymosin mechanism; no direct hair follicle or copper-enzyme activity | Extended protocol combining skin, follicle, and collagen remodeling is the primary goal; GHK-Cu and TB-500 address different tissue repair axes and stack cleanly | Primary goal is systemic diffuse injury healing; TB-500 distributes more broadly for muscle and tendon damage across multiple sites; the BPC-157 + TB-500 blend is optimal for that application |
| Ipamorelin — Dragon Pharma | GH secretagogue (GHRP-type); stimulates pulsatile GH release via ghrelin receptor; anabolic and recovery effects mediated through IGF-1 axis; no direct copper-enzyme or ECM remodeling mechanism | Direct collagen stimulation, skin quality, and hair support are the priority; GHK-Cu + Ipamorelin is a highly synergistic skin and recovery stack — GHK-Cu activates fibroblasts directly while Ipamorelin amplifies GH/IGF-1 for additional collagen turnover | Primary goal is GH-axis activation, sleep quality, or lean body composition — Ipamorelin addresses those through a fundamentally different mechanism |
Combinations and Stacks
| Goal | Stack | Protocol Notes |
|---|---|---|
| Skin anti-aging / collagen quality | GHK-Cu + Ipamorelin | GHK-Cu 1–2 mg/day subQ (morning); Ipamorelin 200–300 mcg subQ before sleep. Direct fibroblast activation (GHK-Cu) + GH/IGF-1 amplification (Ipamorelin) for synergistic collagen and skin thickness improvement. Run 6–8 weeks. At 2 mg/day: one 50 mg vial covers 25 days; two vials cover a full 6-week run (84 mg needed), three vials cover 8 weeks (112 mg needed). |
| Hair loss prevention (extended protocol) | GHK-Cu solo or + Minoxidil Dragon Pharma | GHK-Cu 3 mg/day subQ throughout the AAS cycle. The 50 mg vial covers ~16 days at this dose — plan 4 vials for a full 8-week run (168 mg needed). DHT-independent mechanism: effective on tren, boldenone, DHT-derived compounds where finasteride provides no benefit. Add Minoxidil topically for vasodilatory synergy. |
| Tissue repair (chronic or post-injury) | GHK-Cu + BPC-157 | GHK-Cu 2 mg/day subQ (systemic collagen support and anti-inflammatory); BPC-157 250–500 mcg twice daily near injury site (targeted structural repair). Complementary and non-overlapping mechanisms. Run 4–6 weeks for acute injury; 8 weeks for chronic scar or joint remodeling. At 2 mg/day: one 50 mg vial = 25 days; two vials cover a full 6-week run. |
| Comprehensive repair stack | GHK-Cu + BPC-157 + TB-500 blend + Ipamorelin | GHK-Cu 2 mg/day + BPC-157/TB-500 blend per label + Ipamorelin 200 mcg pre-sleep. Full-spectrum coverage: ECM remodeling (GHK-Cu), structural repair (BPC-157), systemic anti-inflammatory healing (TB-500), GH amplification (Ipamorelin). Off-season recovery or post-cycle phase. Three vials (150 mg) cover a full 8-week run at 2 mg/day (112 mg needed). |
| On-cycle maintenance (multi-cycle) | GHK-Cu solo (low dose), consecutive cycles | 1 mg/day throughout AAS cycle. 50 mg vial yields 50 daily doses (~7 weeks); plan a second vial if running a full 8-week cycle (56 mg needed). Offsets androgenic and oxidative effects on skin and scalp with minimal reconstitution. No hormonal interactions; runs cleanly alongside any AAS, PCT, or peptide stack. Reconstitute in 10 mL Bacteriostatic Water for 5 mg/mL; 1 mg = 0.2 mL. |
Reconstitution for 50 mg vial: add 10 mL of Bacteriostatic Water Dragon Pharma to yield a 5 mg/mL working solution. For a 1 mg dose draw 0.2 mL (20 units on a 100-unit insulin syringe); for 2 mg draw 0.4 mL; for 3 mg draw 0.6 mL. Alternatively, add 5 mL for a 10 mg/mL concentration (1 mg = 0.1 mL) — useful for higher-dose hair protocols where smaller injection volumes are preferred. Reconstituted solution is stable for up to 28 days refrigerated. Swirl gently — do not shake.
Side Effects and How to Manage Them
GHK-Cu is among the best-tolerated injectable peptides in both clinical and performance contexts. Adverse effects at standard doses (1–3 mg/day) are rare and almost always site-related or dose-dependent.
| What May Occur | Background | How to Handle It |
|---|---|---|
| Injection site reactions | Mild redness, transient swelling, or warmth at the injection site — the most commonly reported effect. Resolves within 1–2 hours. More frequent when using the same site repeatedly or injecting volumes above 0.5 mL. | Rotate sites between sessions. Keep injection volume to 0.5 mL or less. At 10 mg/mL concentration (5 mL reconstitution), a 2 mg dose is only 0.2 mL — this minimizes site irritation on higher-dose protocols. |
| Temporary skin flushing or warmth | GHK-Cu stimulates VEGF and local angiogenesis — a brief warming sensation or mild local flushing near the injection site is occasionally reported. Benign and transient; may indicate active vascular response. | No intervention required at standard doses. If systemic flushing occurs, reduce to 0.5 mg/day and titrate up over one week. |
| Mild nausea (rare) | Occasionally reported at doses above 3 mg/day or during the first few days of a new cycle. Attributable to systemic signaling activation rather than GI irritation. | Start at 1 mg/day for the first week before reaching the target dose. Morning injection with food reduces the likelihood. Nausea at 1–2 mg/day is uncommon. |
| Theoretical copper accumulation | Each injection delivers a small copper load — far below dietary copper intake at therapeutic doses. Copper toxicity at standard GHK-Cu doses (1–3 mg/day) is not clinically documented. The primary risk context is very long uninterrupted use without cycling. | Follow the standard 6–8 week on / 2–4 week off schedule. For continuous cosmetic use beyond 12 weeks, a serum copper check is reasonable but rarely reveals actionable abnormalities at these dose levels. |
Bloodwork Monitoring
GHK-Cu has no hormonal activity, no effect on the HPG axis, and no known impact on liver enzymes or lipid profile. Bloodwork requirements are minimal compared to AAS or GH secretagogue protocols.
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Serum copper | Baseline; optional recheck at 3–6 months for continuous extended use | Normal range: 70–140 mcg/dL. Standard cycling doses are unlikely to elevate serum copper meaningfully. If elevated without other explanation, extend the off-cycle break or reduce dose. |
| Zinc | Baseline; optional at 3–6 months | Copper and zinc compete for absorption — prolonged elevated copper intake can depress zinc levels. Normal zinc: 60–120 mcg/dL. Supplement zinc if levels fall below normal range. |
| CBC (Complete Blood Count) | Baseline; standard protocol timing | Standard baseline monitoring. GHK-Cu has no direct hematological effects. If stacking with AAS, hematocrit monitoring is driven by the AAS compounds. |
| CRP / inflammatory markers | Optional — baseline and week 6 for anti-inflammatory use cases | GHK-Cu's NF-κB suppression may be reflected in reduced CRP over a full cycle. Not mandatory, but a useful objective marker for users tracking systemic inflammation response to protocol. |
Protocol and Cycling
GHK-Cu does not suppress endogenous hormones and causes no withdrawal. Cycling in defined blocks is recommended to maximize receptor responsiveness and avoid prolonged continuous copper delivery. The 50 mg vial format is best suited to the longer end of typical cycle durations:
| Protocol Context | Dose | Duration & 50 mg Vial Yield |
|---|---|---|
| Skin anti-aging / collagen maintenance | 1 mg/day subQ | 6–8 weeks on, 2–4 weeks off. One 50 mg vial covers 50 days (~7 weeks); a second vial covers the remaining 6 days for a full 8-week cycle. Results build cumulatively and continue developing during the off period. |
| Hair loss protocol | 2–3 mg/day subQ | 6–8 weeks on, 2–4 weeks off. At 2 mg/day, one 50 mg vial covers 25 days (~3.5 weeks); at 3 mg/day, ~16 days. Plan 3 vials for a full 8-week cycle at 2 mg/day (112 mg needed), or 4 vials at 3 mg/day (168 mg needed). |
| Injury recovery / tissue remodeling | 2–3 mg/day subQ | 4–8 weeks depending on severity. Two vials (100 mg) cover a 4-week acute phase at 3 mg/day (84 mg needed) or a 6-week run at 2 mg/day (84 mg needed). Pair with BPC-157 for acute structural injury. |
| Reconstitution options (50 mg vial) | Option A — 5 mg/mL: add 10 mL Bacteriostatic Water. 1 mg = 0.2 mL; 2 mg = 0.4 mL; 3 mg = 0.6 mL. Standard choice for most protocols. Option B — 10 mg/mL: add 5 mL Bacteriostatic Water Dragon Pharma. 1 mg = 0.1 mL; 2 mg = 0.2 mL; 3 mg = 0.3 mL. Preferred for high-dose hair protocols — smaller injection volumes reduce site irritation. Stable 28 days refrigerated. Swirl gently to dissolve; do not shake. Discard if cloudy or discolored. |
|
Practical Summary
Key rules for using GHK-Cu 50 mg on protocol:
- 50 mg vial is the practical choice for extended stacks — plan vials by dose: at 1 mg/day a single vial covers ~7 weeks; at 2 mg/day — 3 vials for an 8-week run (112 mg needed); at 3 mg/day — 4 vials (168 mg needed); the economics and reduced reconstitution frequency make it standard for ongoing use.
- Compound-agnostic hair support — GHK-Cu stimulates follicle growth through a DHT-independent pathway; it is effective on trenbolone, boldenone, and DHT-derived compound cycles where finasteride is ineffective or contraindicated; combine with Minoxidil for additive vasodilatory effect.
- Two reconstitution options for the 50 mg vial — 10 mL BAC Water → 5 mg/mL (standard); 5 mL BAC Water → 10 mg/mL (preferred for high-dose protocols to keep injection volume below 0.3 mL); Bacteriostatic Water Dragon Pharma in either case — never plain sterile or tap water.
- Pairs cleanly with BPC-157 and TB-500 — GHK-Cu's copper-enzyme and ECM mechanism does not overlap with BPC-157's GH receptor signaling or TB-500's actin pathway; the compounds run together without interaction and address different axes of repair simultaneously.
- Cycle in 6–8 week blocks with a 2–4 week break — no hormonal suppression, no withdrawal; defined cycling prevents desensitization and avoids unnecessary prolonged copper delivery; remodeled collagen continues to mature during the off period.
- No hormonal interactions — runs through any AAS, SERM, or AI protocol — GHK-Cu has no effect on E2, LH, FSH, or testosterone; it can be added to or removed from any phase of a cycle without endocrine adjustment.
GHK-Cu Dragon Pharma 50 mg is the format of choice for athletes at Steroid Warehouse who are running GHK-Cu as a continuous on-cycle tool rather than a single short addition. The 50 mg vial covers the full dose requirements for extended hair loss prevention, multi-week injury recovery, or a stacked anti-aging protocol — with the convenience of a single reconstitution that lasts the majority of a cycle. At 1–3 mg/day, GHK-Cu delivers cumulative improvements in collagen architecture, scalp environment, and anti-inflammatory tone that compound over time and justify sustained use across consecutive cycles.
References
| Source | Relevance | Link |
|---|---|---|
| International Journal of Molecular Sciences / PubMed | Pickart & Margolina 2018 — comprehensive review of GHK-Cu regenerative and protective actions, including skin repair, collagen and elastin support, glycosaminoglycan synthesis, antioxidant activity, anti-inflammatory signaling, angiogenesis, and gene-expression effects | Pickart L & Margolina A (2018) ↗ |
| Journal of Biomaterials Science, Polymer Edition / PubMed | Pickart 2008 — detailed review of the human tripeptide GHK and tissue remodeling; covers GHK-Cu formation, copper binding, fibroblast and keratinocyte activity, wound healing, collagen and elastin synthesis, angiogenesis, and skin regeneration context | Pickart L (2008) ↗ |
| Oxidative Medicine and Cellular Longevity / PubMed | Pickart et al. 2012 — review of GHK-Cu in oxidative stress and degenerative aging mechanisms; covers antioxidant defense, anti-inflammatory effects, copper binding, tissue protection, and broader regenerative biology | Pickart L, et al. (2012) ↗ |
| Archives of Pharmacal Research / PubMed | Pyo et al. 2007 — in vitro study of a related tripeptide-copper complex, AHK-Cu, on human hair follicle elongation and dermal papilla cell proliferation; supporting copper-peptide hair-growth context | Pyo HK, et al. (2007) ↗ |
| BioMed Research International / PubMed | Pickart et al. 2015 — review describing GHK as a natural modulator of multiple cellular pathways in skin regeneration, including wound repair, extracellular matrix remodeling, anti-inflammatory activity, and gene-expression regulation | Pickart L, et al. (2015) ↗ |
What is GHK-Cu peptide used for?
It promotes skin regeneration; see What is GHK-Cu Peptide Used For. It's effective—consult professionals for safe use.
What is GHK used for?
It supports repair and anti-aging; see What is GHK Used For. Monitor with care—consult professionals.
Is GHK-Cu safe to use?
It can be safe with oversight; see Is GHK-Cu Safe to Use. Use with guidance—consult professionals.
How quickly does GHK-Cu work?
Results in 2-4 weeks; see How Quickly Does GHK-Cu Work. Monitor progress—consult professionals.
What is GHK-Cu commonly used for?
GHK-Cu is commonly associated with:
- Skin rejuvenation support
- Hair and scalp wellness
- Recovery and tissue repair research
- Anti-aging and cosmetic-focused protocols
It is widely discussed in peptide wellness and skincare communities.
Why is GHK-Cu popular in skincare and wellness protocols?
Users often choose GHK-Cu because it may:
- Support skin texture and elasticity
- Promote healthier-looking hair and scalp conditions
- Complement anti-aging and recovery-focused routines
It is commonly included in cosmetic and wellness peptide discussions
Related Products
- Enhances cellular energy production.
- Supports anti-aging and DNA repair.
- Improves metabolic health.
- Promotes overall vitality.